TMO Stock Analysis — Thermo Fisher Scientific
Sector: Healthcare
AI Verdict
Thermo Fisher trades at a fair price for the explosive growth analysts expect, but the stock is priced for near perfection and could see a quick correction if its integrated moat doesn't deliver.
Competitive Moat
Thermo Fisher dominates life sciences tools through a vast portfolio of proprietary instruments, consumables, and services that are deeply embedded in research and clinical workflows. Its scale and integration across diagnostics, lab equipment, and specialty manufacturing create high switching costs for customers.
Summary
Thermo Fisher is in focus as analysts expect a 48.9% jump in earnings next year, driving a sharp drop in its forward P/E.
Where It Stands
TMO is up 24.39% over the past year, trades at 21.8x next year's earnings (below the healthcare median of 22x), and its RSI of 68.2 signals elevated pullback risk.
Key Metrics
- RSI: 68.2 — Near Overbought
- Trailing P/E: 32.5x
- Forward P/E: 21.8x
- PEG Ratio: 0.66
- Earnings Growth: +0.5%
- Revenue Growth: +0.1%
- Market Cap: $223.0B
- Dividend Yield: 0.00%
- 1-Year Return: 24.39%
- 52-Week High: $643.99
- 52-Week Low: $435.27
Analyst Consensus
29 Buy · 7 Hold · 0 Sell (36 analysts)
Bull Case
You're paying 21.8x forward earnings for nearly 49% expected EPS growth, which is cheap for the growth on offer if Thermo Fisher executes.
Bear Case
With an RSI at 68.2 and a trailing P/E of 32.5x, a pullback to the sector median 22x would mean a 32% valuation drop if growth stumbles.
Catalyst to Watch
Watch for quarterly earnings updates — any sign that EPS growth won't hit the 48.9% target could trigger a sharp rerating.